Neuroendocrine Carcinoma
Oncology
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
2100%
+ 1 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Qilu PharmaceuticalChina - Jinan
1 program1
Nab-paclitaxel Combined With BevacizumabPhase 2Monoclonal Antibody1 trial
Active Trials
M&
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Qilu PharmaceuticalNab-paclitaxel Combined With Bevacizumab
Merck & Co.Pembrolizumab
RadioMedix68Ga-DOTATATE
Clinical Trials (3)
Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma
Start: Jan 2021Est. completion: Sep 2024
Phase 2Completed
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
Start: Oct 2019Est. completion: Jan 20210
Phase 2Withdrawn
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
Start: Mar 2013Est. completion: Dec 2017
N/ACompleted
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
8m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
8m ago
Office Administrator
SystImmune
8m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
19m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
22m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
22m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Monoclonal Antibody is the dominant modality (100% of programs)
3 companies competing in this space